SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

Core Viewpoint - Investors are expected to focus on Sol-Gel Technologies, Ltd.'s compliance with Nasdaq requirements and pipeline developments during the upcoming fourth-quarter and full-year 2024 results announcement [1]. Financial Performance - The Zacks Consensus Estimate for the upcoming quarter's revenues is $2 million, with an expected loss of 11 cents per share [1][12]. - Over the past year, Sol-Gel's shares have decreased by 46.2%, contrasting with a 1.9% increase in the industry [2]. Product Development - Sol-Gel has developed Twyneo and Epsolay, both FDA-approved treatments for acne vulgaris and rosacea, respectively [4]. - The company has licensing agreements for Twyneo and Epsolay, which generate royalties and milestone payments [4]. - Sol-Gel is also collaborating with Padagis for the development of a generic version of Zoryve Cream [5]. Revenue Sources - The company's revenue is primarily derived from licensing agreements with partners such as Padagis, Galderma, and Searchlight Pharma, with expectations of increased licensing revenues in the upcoming quarter [5]. Pipeline Candidates - The key pipeline candidate, SGT-610, is in phase III development for Gorlin Syndrome, with top-line data expected in the second half of 2026 [6]. - A proof-of-concept study for SGT-210, aimed at treating Darier disease, is also underway [6]. Compliance and Regulatory Updates - In November 2024, Sol-Gel received a notification from Nasdaq regarding the transfer of its shares to The Nasdaq Capital Market due to non-compliance with the Minimum Bid Price Requirement, with an additional 180 days granted to regain compliance [9]. Earnings Surprise History - Sol-Gel has a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 41.93% [10].